Aurobindo Pharma receives USFDA approval for Amoxicillin for Oral Suspension

16 Sep 2014 Evaluate

Aurobindo Pharma has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL.

Amoxicillin for Oral Suspension USP 125mg/5mL and 250mg/5mL is the generic equivalent to the reference listed drug product (RLD), Amoxicillin for Oral Suspension, 125mg/5 mL and 250mg/5mL respectively of Teva Pharmaceutical Industries and indicated in the treatment of infections due to susceptible βetalactamase-negative strains of the designated microorganisms.

According to IMS, the product has a market size of approximately $19 million for the twelve months ending July 2014. These ANDAs has been approved out of Unit XII, Semi-Synthetic Penicillin (SSP) formulation facility in Hyderabad, India.

Aurobindo now has a total of 195 ANDA approvals (169 Final approvals including 7 from Aurolife Pharma LLC and 26 Tentative approvals) from USFDA. 

Aurobindo Pharma Share Price

1181.20 -6.00 (-0.51%)
31-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1719.75
Dr. Reddys Lab 1271.05
Cipla 1510.90
Zydus Lifesciences 914.65
Lupin 2112.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×